The ALDH1B1 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human CAL-27 tongue squamous cell carcinoma cell line, designed for targeted disruption of the ALDH1B1 locus. This loss-of-function model enables investigation of ALDH1B1-dependent processes without the confounding effects of clonal selection, providing a genetically heterogeneous pool that mirrors natural variation while abolishing gene function. The knockout product format is polyclonal, ensuring representation of diverse editing outcomes while maintaining robust disruption of ALDH1B1 expression, suitable for a broad range of functional genomic applications.
The host cell line, CAL-27, is an epithelial cell line originally isolated from a 56-year-old male patient with tongue squamous cell carcinoma. CAL-27 cells exhibit typical epithelial morphology and are widely employed as an in vitro model system for oral squamous cell carcinoma and head and neck cancer research. This cell line retains key characteristics of the tumor microenvironment and has been extensively characterized for studies involving cancer cell biology, drug response, and metastatic potential. Its relevance to oral carcinogenesis makes it an ideal platform for examining the role of ALDH1B1 in this malignancy.
ALDH1B1 encodes a mitochondrial aldehyde dehydrogenase that catalyzes the irreversible oxidation of both aliphatic and aromatic aldehydes, including acetaldehyde and retinaldehyde. Functionally, ALDH1B1 is activated by transcription factors such as HNF4A, PPARGC1A, NFE2L2 (NRF2), and is regulated downstream of WNT/??-catenin signaling. It interacts with the mitochondrial import machinery and molecular chaperones HSP60/HSP10, and functionally partners with ALDH2 in aldehyde detoxification. The enzyme plays a pivotal role in retinoic acid biosynthesis by converting retinaldehyde to retinoic acid, which then serves as a ligand for RAR/RXR nuclear receptors, thereby modulating gene expression. Additionally, ALDH1B1 contributes to ethanol metabolism via the ADH1B-ALDH2-CYP2E1 axis and participates in pyruvate metabolism and fatty acid degradation pathways, collectively influencing cellular redox balance and detoxification capacity.
In the context of CAL-27 oral squamous cell carcinoma cells, ALDH1B1 activity has been implicated in promoting cancer stem cell properties and chemoresistance. By detoxifying reactive aldehydes, it reduces oxidative stress and may protect cells against cytotoxic agents, including cisplatin. Furthermore, ALDH1B1-mediated retinoic acid signaling can drive stemness-related gene expression, contributing to tumor initiation and maintenance. Thus, knockout of ALDH1B1 in this model provides a powerful tool to dissect how mitochondrial aldehyde metabolism impacts tumorigenic potential, drug sensitivity, and redox homeostasis specifically in oral cancer cells.
This polyclonal knockout cell model is suited for a wide range of experimental investigations, including functional assays for oral squamous cell carcinoma biology, aldehyde detoxification studies, and analysis of cellular redox state. Researchers may employ techniques such as ALDEFLUOR assay to assess aldehyde dehydrogenase activity, sphere formation assays for stem cell properties, retinoic acid reporter assays, and cell viability or drug sensitivity assays using cisplatin. Additional applications include Western blotting, RT-qPCR, metabolomics, and migration assays to elucidate the mechanistic contributions of ALDH1B1 to cancer metabolism and progression. For further details or technical support, please contact Ascent Research.
